

eISBN: 978-1-68108-155-7
ISBN: 978-1-68108-156-4

eISSN: 2210-268X
ISSN: 2452-3240

Anti-Angiogenesis Drug Discovery and Development

Volume 3

Editors:

Atta-ur-Rahman
M. Iqbal Choudhary

Bentham  Books

Anti-Angiogenesis Drug Discovery and Development

(Volume 3)

Edited by

Atta-ur-Rahman, *FRS*

Kings College

University of Cambridge

Cambridge

UK

&

M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry

International Center for Chemical and Biological Sciences

University of Karachi

Karachi

Pakistan

Anti-Angiogenesis Drug Discovery and Development

Volume # 3

Editors: Atta-ur-Rahman and Iqbal Choudhary

ISSN (Online): 2210-268X

ISSN (Print): 2452-3240

ISBN (Online): 978-1-68108-155-7

ISBN (Print): 978-1-68108-156-4

© 2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org



CONTENTS

| | |
|---|-----------|
| PREFACE | i |
| LIST OF CONTRIBUTORS | kv |
| CHAPTER 1 BETA-BLOCKER THERAPY FOR RETINOPATHY OF PREMATURITY | 3 |
| <i>Kó cf "T00cnj qwn"Vcylcpc"Ub qmkp"cpf "F cxf "Y ct dwt vqp</i> | |
| 1. WHAT IS ALREADY KNOWN ON THIS TOPIC | 4 |
| 2. WHAT THIS CHAPTER ADDS | 4 |
| 3. INTRODUCTION | 4 |
| 4. FEASIBILITY AND EFFECTIVENESS OF ANTI-ANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY | 6 |
| Oral Propranolol for Premature Infants with ROP | 7 |
| 4.2. Propranolol Safety and Future in Premature Infants with ROP | 11 |
| 4.3. Ongoing Trials of Propranolol for ROP | 12 |
| 5. FUTURE RESEARCH | 13 |
| ABBREVIATIONS | 13 |
| CONFLICT OF INTEREST | 13 |
| ACKNOWLEDGEMENTS | 13 |
| REFERENCES | 13 |
| CHAPTER 2 DISINTEGRIN-BASED, SYNTHETIC CYCLIC KTS PEPTIDES AS NOVEL DUAL ANTAGONISTS OF A1B1/A2B1 INTEGRINS WITH ANTIANGIOGENIC ACTIVITY | 16 |
| <i>Vcylcpc"O qo ke."Lgj quj we"Mcyl gj gpf rgt."Glt cv"P qf."J cpqej "Ugpf gt qy kf."Lqj cppgu"COGdrg."</i> | |
| <i>Egl ct{"O ct elpknky kel"cpf "Rj klr"Ne ct qxlek</i> | |
| 30 ^o ANGIOGENESIS | 17 |
| *****40 ^o 1 β 1 AND α 2 β 1 INTEGRINS ARE TARGETS IN ANGIOGENESIS*****..... | 18 |
| 3. ANTIANGIOGENIC PEPTIDES IN DRUG DEVELOPMENT | 19 |
| 4. COMPUTATIONAL APPROACHES IN ANTIANGIOGENIC PEPTIDE DRUG DISCOVERY | 20 |
| 5. SNAKE VENOMS DISINTEGRINS | 22 |
| 6. KTS PEPTIDES, PARTIAL ANTAGONISTS OF A1B1 AND A2B1 INTEGRINS | 23 |
| 6.1. Synthesis of KTS Peptides | 23 |
| 6.2. Modeling of KTS Cyclic Peptides in Water | 26 |
| 6.3. Antiangiogenic Activities of KTS Cyclic Peptides | 30 |
| 6.4. Stability and Safety of KTS Cyclic Peptides | 33 |
| 6.5. KTS Cyclic Peptides Increase Survival of Mice with Melanoma Tumors | 34 |
| CONCLUDING REMARKS | 34 |
| CONFLICT OF INTEREST | 36 |
| ACKNOWLEDGEMENTS | 36 |
| REFERENCES | 36 |
| CHAPTER 3 CURRENT STATUS OF ANTI-ANGIOGENIC THERAPY IN THE CLINICAL MANAGEMENT OF LUNG CANCER | 46 |
| <i>Rgvgt"O0Gnku"cpf "Cdf wx k "CrlHctuk</i> | |
| 1. ANGIOGENESIS IN THE PATHOGENESIS OF LUNG CANCER | 47 |
| 2. MONOCLONAL ANTIBODIES AS ANTI-ANGIOGENIC THERAPY | 50 |
| 2.1. Bevacizumab in Combination with Platinum-Based Chemotherapy for the First-Line Therapy of NSCLC | 50 |
| 2.2. Other Intravenous Anti-Angiogenic Compounds in First-Line Therapy for NSCLC | 56 |
| 2.3. The Role of Anti-Angiogenic Therapy Upon Disease Progression | 58 |
| 2.3a. Bevacizumab | 58 |
| 2.3b. Ramucirumab | 58 |
| 2.3c. Aflibercept | 60 |

| | |
|--|-----------|
| 2.4. Bevacizumab in Adjuvant, Locally Advanced, or Neoadjuvant Treatment of Advanced NSCLC | 60 |
| 3. SMALL MOLECULE ORAL ANTI-ANGIOGENIC COMPOUNDS IN THE FIRST-LINE THERAPY OF NSCLC | 61 |
| 3.1. Inhibition of a Single Angiogenic Pathway Alone | 62 |
| 3.1a. Vandetanib | 62 |
| 3.2a. Cediranib | 65 |
| 3.2b. Sorafenib | 65 |
| 3.2c. Motesanib | 66 |
| 3.2d. Axitinib | 67 |
| 3.2e. Linifanib | 68 |
| 3.2f. Pazopanib | 68 |
| 4. TRIALS OF ORAL ANTI-ANGIOGENIC COMPOUNDS AFTER FAILURE OF FIRST-LINE THERAPY FOR NSCLC | 69 |
| 4.1. Inhibition of Vascular Endothelial Growth Factor Receptor Alone | 71 |
| 4.1a. Vandetanib | 71 |
| 4.1b. Cabozantinib | 72 |
| 4.2a. Nintedanib | 73 |
| 4.2b. Sunitinib | 74 |
| 4.2c. Sorafenib | 75 |
| 4.2d. Linifanib | 76 |
| 4.2e. Cediranib | 76 |
| 5. ANTI-ANGIOGENIC THERAPY IN SCLC | 77 |
| 5.1. Bevacizumab | 79 |
| 5.2. Sunitinib | 80 |
| 5.3. Vandetanib | 81 |
| 5.4. Sorafenib | 81 |
| 5.5. Thalidomide and Other Immunomodulatory Agents | 81 |
| 5.6. Aflibercept | 82 |
| CONCLUSION | 82 |
| CONFLICT OF INTEREST | 84 |
| ACKNOWLEDGEMENTS | 84 |
| REFERENCES | 84 |

CHAPTER 4 ANGIOGENESIS IN HEPATOCELLULAR CARCINOMA (HCC) AND ITS POTENTIAL APPLICATIONS IN THE DEVELOPMENT OF ANTI-HCC DRUGS 97

I wcpj /Ej wp"Uwp. F ckY gk\ j cq. 'Zw' cpi "cpf 'Nkej wp"Uwp

| | |
|---|------------|
| 1. INTRODUCTION | 98 |
| 2. ANGIOGENESIS AND ITS REGULATION IN HEPATOCELLULAR CARCINOMA | 100 |
| 2.1. Angiogenesis Factors in Hepatocellular Carcinoma | 101 |
| 2.1.1. VEGF | 101 |
| 2.1.2. HDGF | 102 |
| 2.1.3. FGFs | 102 |
| 2.1.4. Angiopoietin | 103 |
| 2.1.5. Other Angiogenic Factors | 103 |
| 2.2. Anti-angiogenic Factors in Hepatocellular Carcinoma | 104 |
| 2.2.1. Endostatin | 104 |
| 2.2.2. Angiostatin | 105 |
| 2.2.3. Thrombospondin (TSP) | 105 |
| 2.2.4. Tissue Inhibitors of Metalloproteinases (TIMPs) | 106 |
| 3. ANTI-ANGIOGENIC THERAPEUTICS IN HEPATOCELLULAR CARCINOMA | 107 |
| 3.1. Molecular Targeting Drugs Against HCC Angiogenesis | 109 |
| 3.1.1. Sorafenib | 110 |

| | |
|--|-----|
| 3.1.2. Sunitinib | 111 |
| 3.1.3. Brivanib | 113 |
| 3.1.4. Linifanib (ABT-869) | 115 |
| 3.1.5. Axitinib | 116 |
| 3.1.6. Cediranib | 118 |
| 3.1.7. TSU-68 | 119 |
| 3.2. Anti-HCC Angiogenic Inhibitors Tested in Clinic | 120 |
| 3.2.1. Bevacizumab | 120 |
| 3.2.2. Thalidomide | 121 |
| 3.2.3. Endostatin | 122 |
| 3.2.4. Interferon Alpha (IFN- α) | 123 |
| 3.2.5. COX Inhibitors | 125 |
| 3.3. Anti-HCC Angiogenic Inhibitors under Experimental Evaluation | 127 |
| 3.3.1. TNP-470 | 127 |
| 3.3.2. Batimastat (BB-94) | 129 |
| 3.3.3. Interleukin 12 (IL-12) | 129 |
| 3.3.4. PTK 787 | 131 |
| 4. THE COMBINATION STRATEGIES AGAINST HEPATOCELLULAR CARCINOMA | 133 |
| 4.1. Anti-angiogenic Agents in Combination with Chemotherapy or Radiotherapy | 133 |
| 4.2. Anti-angiogenic Agents in Combination with Metronomic Chemotherapy | 134 |
| 5. OPTIMIZATION OF CLINICAL STUDIES IN ANTI-ANGIOGENIC THERAPEUTICS | 135 |
| 6. OPTIMIZATION OF CLINICAL STUDIES IN ANTI-ANGIOGENIC THERAPEUTICS | 137 |
| CONCLUSION | 138 |
| ABBREVIATIONS | 139 |
| CONFLICT OF INTEREST | 141 |
| ACKNOWLEDGEMENTS | 142 |
| REFERENCES | 142 |

CHAPTER 5 BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT: REVIEWING BIOLOGICAL AND CLINICAL HYPOTHESES FOR ITS SUCCESS AND FAILURES

*Cpc'E0Hgtpcpf gu'Erf wf kc'Ecgkq.'Xgtc'Oktcpfc/I qp±κgu'Hgtpcpf c'Ewt f.'Octi ctlf c'Fco cuegpq.
Tw'KOOTglu'cpf'Qri c'O ct vtpj q*

| | |
|---|-----|
| 1. INTRODUCTION | 176 |
| 2. CLINICAL RESULTS OF BEVACIZUMAB IN GLIOBLASTOMA | 179 |
| 2.1. Efficacy in Recurrent Glioblastoma | 179 |
| 2.2. Efficacy in Newly Diagnosed Glioblastoma | 184 |
| 2.3. Bevacizumab Safety | 189 |
| 2.4. Quality of Life | 191 |
| 2.5. Response Assessment | 194 |
| 3. MOLECULAR AND BIOLOGICAL FEATURES OF GLIOBLASTOMA RESPONSE TO BEVACIZUMAB | 197 |
| 3.1. Potential Predictive Biomarkers of Response to Bevacizumab | 197 |
| 3.1.1. Tumor Tissue Biomarkers | 197 |
| 3.1.2. Circulating Blood Biomarkers | 199 |
| 3.2. Putative Molecular Mechanisms Underlying Resistance to Bevacizumab | 201 |
| 3.2.1. VEGF Independent Vessels Growth | 201 |
| 3.2.2. Bevacizumab-induced Hypoxia | 202 |
| 3.2.3. Bevacizumab-induced Invasion | 204 |
| 3.2.4. Metabolic Reprogramming | 205 |
| 3.2.5. Alternative Mediators of Bevacizumab Resistance | 208 |
| CONCLUDING REMARKS | 209 |
| CONFLICT OF INTEREST | 210 |
| ACKNOWLEDGEMENTS | 210 |

| | |
|----------------------------|-----|
| REFERENCES | 210 |
| SUBJECT INDEX | 227 |

PREFACE

Angiogenesis is a normal process for healing and reproduction. It involves the growth of new capillary blood vessels from the pre-existing vessels. However, in disease states angiogenesis leads to abnormal blood vessel growth. This then becomes the underlying process for many deadly diseases, including cancers and retinopathy. Pharmaceutical R&D is currently focused on devising strategies to target biochemical and cellular events involved in the angiogenesis in search of treatment of various diseases. An important approach has been to inhibit the action of various enzymes and factors involved in the complex cascade of reactions leading to new blood vessel formation.

The 3rd volume of the book series “*Anti-Angiogenesis Drug Discovery and Development*” is a compilation of five excellent reviews, written by leading researchers in these fields. Each review is focused on a certain important aspect of angiogenesis and the modulation of the angiogenesis process through chemotherapeutic agents as possible treatments of various diseases.

Makhouli *et al.* have contributed a review on various clinical and pre-clinical trials on beta-blockers, such as catecholamine, for the treatment of retinopathy of prematurity (ROP). ROP is a disease of premature babies, which involves abnormal blood vessel formation in the retina. This growth can cause the retina to detach from the back of the eye, leading to complete blindness. The diseases range from being mild to severe and currently no treatment is available. The authors have summarized the results of various clinical and preclinical studies of oral propranolol treatment, and evaluated the efficacy and safety of such treatment at various stages of ROP. Propranolol is used in the treatment of tremors hypertension (high blood pressure), heart rhythm disorders, angina (chest pain), and in other heart or circulatory disorders. It is also used to prevent heart attack, and reduce the severity and frequency of migraine headaches. The use of propranolol in ROP is an important step forward, as well as an example of drug repurposing.

Integrins represent a family of adhesion receptor proteins involved in angiogenesis. The review contributed by Lazarovici *et al.* is focused on the development of antagonists (disintegrins) of various types of integrins for therapeutic purposes. Obtustatin and viperistatin, two members of the disintegrin protein family, have been used as templates for the synthesis of two linear and cyclic peptides, containing the KTS binding motif. More specifically, two synthetic cyclic linear peptides, vimocin and vidapin, have attracted major scientific interests as dual antagonists of $\alpha 1/\alpha 2$ integrins. *In vitro* and *in vivo* studies indicated their high potency in inhibiting the adhesion of integrins, thus slowing down the angiogenesis induced by vascular endothelial growth factors. The results of various studies, including

stability, potency, efficacy, computational modeling, etc. indicate the promising nature of vimocin and vidapin.

The last three reviews are focused on the therapeutic potential of various antiangiogenic drug candidates in the treatment of cancers, such as lung cancer, hepatocellular carcinoma, and glioblastoma. All three reviews start with the detail descriptions of the role of angiogenesis in tumor progression, and molecular events in angiogenic process, followed by the development of various anti-angiogenic compounds to inhibit the angiogenesis cascade as potential drugs. The results of animal studies and clinical trials present a mixed picture, which demands further studies in this field.

Ellis and Al Farsi review the current status of antiangiogenic therapy in the treatment of lung cancer, known for very high level of angiogenic activity, aggressive nature, and very low survival rate. Antiangiogenic drugs can offer a better therapeutic option for lung cancer, and thus vigorous research is being conducted on this class of potential drugs. The authors have exhaustively reviewed the results of clinical studies on various combinations of therapeutic agents *i.e.* antiangiogenic monoclonal antibody bevacizumab and various classes of anti-cancer drugs, on the improvement of survival, disease progression, tumor recurrence, and metastasis in NSCLC (Non-small cell lung cancer) patients. The results of these studies were found to be non-conclusive, though some improvement in survival rate has been noted. The authors present a strong case in favor of further studies in the identification of biomarkers, as well as additional translational research.

Hepatocellular carcinoma (HCC) is the most malignant tumor with a very high mortality rate. Available treatment options are few, and far from ideal. HCC is known for the high level of neo-angiogenesis. A series of angiogenic factors have been identified in HCC as possible targets for anti-angiogenic drug discovery. Recently, several anti-angiogenic agents were developed, and extensive animal studies and clinical trials have been conducted. The review, contributed by Sun *et al.*, describes the salient features of various clinical and pre-clinical studies, as well as limitation, challenges, and recent advances in the possible treatment of HCC by anti-angiogenic agents, and their combinations with classical anti-HCC drugs.

The last review of this volume, contributed by Martinho *et al.*, focuses on the treatment of glioblastoma multiforme (GBM) by an FDA approved anti-angiogenic monoclonal antibody, bevacizumab. The results of clinical trials on bevacizumab in combination with radiotherapy and the anti-cancer drug temozolomide (TMZ) have shown improved survival rate in GBM patients. However, data about the quality of life, and functional improvements are conflicting. Reports of adverse effects of bevacizumab further complicate the situation. This requires a better understanding of the biology and mechanism of the angiogenic process involved in the progression of GBM, and improved clinical study design.

We wish to express our gratitude to all the eminent contributors for the timely submission of their articles which have resulted in this excellent 3rd volume of the eBook series volume in this important field. It is the result of efficient coordination and excellent management of the entire team of Bentham Science Publishers. We would like to appreciate the joint efforts of Mr. Omer Shafi (Assistant Manager Publications), Mr. Shehzad Naqvi (Manager Publications) and team leader Mr. Mahmood Alam (Director Publications). We sincerely hope that this volume will receive wide appreciation from the readers.

Atta-ur-Rahman, FRS

Kings College
University of Cambridge
Cambridge
UK
&

M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan

List of Contributors

- Abdulaziz Al Farsi** Staff Medical Oncologist, Juravinski Cancer Centre, Hamilton, Ontario, Canada
Clinical Research Fellow in Lung Cancer, Department of Oncology, McMaster University, Hamilton, Ontario, Canada
- Ana C. Fernandes** Department of Oncology, Centro Hospitalar S. João, Porto, Portugal
- Cezary Marcinkiewicz** Department of Bioengineering, College of Engineering, Temple University, Philadelphia, Pennsylvania, USA
- Cláudia Caeiro** Department of Oncology, Centro Hospitalar S. João, Porto, Portugal
- Dai-Wei Zhao** Department of Surgery, The Second Affiliated Hospital of Guiyang Medical University, 3 Kang-Fu Rd., Kaili 556000, China
- David Warburton** Children's Hospital Los Angeles, The Haim Saban Research Institute, Developmental Biology and Regenerative Medicine Program, Keck School of Medicine and Ostrow School of Dentistry University of Southern California, Los Angeles, CA, USA
- Efrat Noy** Department of Chemistry, Bar Ilan University, Ramat-Gan, Israel
- Fernanda Cury** Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
- Guang-Chun Sun** Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, 801 He-Qing Rd., Shanghai 200240, China
- Hanoeh Senderowitz** Department of Chemistry, Bar Ilan University, Ramat-Gan, Israel
- Imad R. Makhoul** Department of Neonatology, Ruth Rappaport Children's Hospital, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
- Jehoshua Katzehandler** School of Pharmacy, Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
- Johannes A. Eble** Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany
- Lichun Sun** Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, 801 He-Qing Rd., Shanghai 200240, China.
Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy & Pharmacology, University of South China, Hengyang, 421001, China.
Department of Medicine, School of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112-2699, USA
- Margarida Damasceno** Department of Oncology, Centro Hospitalar S. João, Porto, Portugal

| | |
|-------------------------------|---|
| Olga Martinho | Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil |
| Peter M. Ellis | Department of Oncology, McMaster University, Hamilton, Ontario, Canada |
| Philip Lazarovici | School of Pharmacy, Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel |
| Rui M. Reis | Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil |
| Tatiana Smolkin | Department of Neonatology, Ruth Rappaport Children's Hospital, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel |
| Tatjana Momic | School of Pharmacy, Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel |
| Vera Miranda-Gonçalves | Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal |
| Xu Yang | Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, 801 He-Qing Rd., Shanghai 200240, China |

Beta-Blocker Therapy for Retinopathy of Prematurity

Imad R. Makhoul^{1,*}, Tatiana Smolkin¹ and David Warburton²

¹ Department of Neonatology, Ruth Rappaport Children's Hospital, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

² Children's Hospital Los Angeles, The Haim Saban Research Institute, Developmental Biology and Regenerative Medicine Program, Keck School of Medicine and Ostrow School of Dentistry University of Southern California, Los Angeles, CA, USA

Abstract: Vascular endothelial growth factor (VEGF) plays a critical role in the pathogenesis of the vaso-proliferative phase of retinopathy of prematurity (ROP), being up-regulated by the adrenergic system and down-regulated by beta-blockers. Beta-blockers are anti-angiogenic agents and as such they decelerate the growth of skin hemangiomas and decrease the risks associated with life-threatening hemangiomas. Numerous previous studies investigated the effect of catechol amines on the angiogenesis of various cells in culture or on relevant animal models of angiogenesis. As of April 2015, two prospective randomized trials recently evaluated oral propranolol treatment for established ROP. Mahout *et al.* studied 20 premature infants with ROP (10–oral propranolol, 10–placebo) and showed a 50% reduction of need for invasive interventions. Filippo *et al.* treated 52 infants with ROP using oral propranolol and achieved 48% and 58% risk reduction of progression to stage 3 and stage 3 plus ROP, respectively, and a 52% reduction in the need for laser or bevacizumab therapy. To avoid systemic adverse effects of oral propranolol, rabbits and mice with oxygen-induced retinopathy (OIR) recently received propranolol eye drops, producing retinal concentrations similar to those measured after oral administration but with significantly lower plasma concentrations. Propranolol eye drops promoted OIR recovery in mice. Although the systemic (oral) or topical (eye drops) routes for beta-blocker therapy for ROP appear promising, questions have emerged regarding effectiveness, safety, tolerability and timing of treatment. Additionally, should beta-blockers prove safe and

* **Corresponding author Imad R. Makhoul:** Department of Neonatology, Rambam Medical Center, Bat-Galim, Haifa 31096, Israel; Tel: 972-4-7774116; Fax: 972-4-7774126; E-mail: makhoul@rambam.health.gov.il

effective for ROP in premature infants, then the optimal therapeutic approach should be determined: Rescue Therapy for established ROP *versus* pre-emptive prophylactic treatment in premature infants at high risk for developing ROP, mainly those born prior to 28 weeks' gestation. In this chapter we review the literature as to the discovery of the key role of catechol amines on angiogenesis and their effects *via* VEGF as well as the approaches taken to implement anti-angiogenic therapy for ROP in animals and humans.

Keywords: Angiogenesis, Beta adrenergic receptors, Bevacizumab, Cancer, Catechol amines, Cell culture, Epinephrine, Neo-vascularization, Oxygen induced retinopathy, Propranolol, Retinopathy of prematurity, Vascular endothelial growth factor.

1. WHAT IS ALREADY KNOWN ON THIS TOPIC

The management of retinopathy of prematurity is currently expectant with invasive interventions (laser photocoagulation of ischaemic retina for threshold ROP or intravitreal injection of bevacizumab) being performed as "rescue" therapies. Nowadays, non-invasive medical therapies for earlier stages of ROP are being considered.

2. WHAT THIS CHAPTER ADDS

Oral propranolol is apparently safe when given as systemic therapy to premature infants with retinopathy of prematurity. Propranolol could reduce by about half the need for invasive interventions for retinopathy of prematurity (laser photocoagulation and intravitreal injection of bevacizumab). Studies are underway now for evaluation of earlier initiation of propranolol therapy in premature infants who are potential candidates for development of ROP. In addition, topical eye propranolol drops are compared to systemic oral propranolol therapy.

3. INTRODUCTION

Retinopathy of prematurity (ROP) occurs mainly in premature infants born before 28 weeks' gestation. Extreme prematurity and relative hyperoxia are the main risk factors for ROP while aberrant angiogenesis of the retinal vasculature is the

common pathogenetic pathway of ROP. So far, the main therapeutic modalities for ROP include destruction of retinal areas with aberrant angiogenesis by laser photocoagulation or by medications with anti-angiogenic activity.

Stimulation of beta adrenergic receptors (β -AR) by either epinephrine or norepinephrine (NE), down regulates neo-vascularization [1]. Noteworthy are the key role of VEGF in retinal neovascularization and the successful therapeutic trials with VEGF blockers. Hence, improving animal models of oxygen-induced retinopathy (OIR) is equally important for investigating anti-angiogenic therapies. Rezzola *et al.* [2] developed a novel murine retina angiogenesis assay where retinal fragments from adult mice were embedded in a fibrin gel in the presence of human recombinant VEGF. Starting from the 3rd-4th day of incubation, endothelial cell sprouts invaded the fibrin gel. The effect of VEGF was dose-dependent, with maximal stimulation being observed after 7 days. As to potential toxicity of bevacizumab, Kaempf *et al.* [3] found bevacizumab to be well tolerated by ganglion and photoreceptor cells.

In a mouse model of OIR, Dal Monte *et al.* [4] have recently shown that subcutaneous (sc) administration of the non-selective β -AR blocker propranolol ameliorates angiogenic processes in the retina when its effects are evaluated at postnatal day (PD) 17. After propranolol administration on the eye, mice were first tested for retinal concentrations of propranolol as compared with those measured after sc or per os administration. The results showed that 2% topical propranolol has efficiency (in terms of final propranolol concentration in the retina) comparable to that of 20 mg/kg propranolol sc or per os which is significantly higher than those observed with doses and administration routes that are currently used with children [4].

Propranolol ophthalmic solutions reduced VEGF and IGF-1 up-regulation in response to hypoxia. As a result of its inhibitory effects on hypoxia-induced proangiogenic factors, propranolol significantly lessened retinal neovascularization in the superficial but not in the deep vascular plexus. An evaluation of retinal neovascularization at PD21 showed that propranolol was still effective in inhibiting OIR. These findings support the hypothesis that β -AR blockade can efficiently counteract OIR and suggest that topical eye application

Disintegrin-Based, Synthetic Cyclic KTS Peptides as Novel Dual Antagonists of $\alpha1\beta1/\alpha2\beta1$ Integrins with Antiangiogenic Activity

Tatjana Momic¹, Jehoshua Katzehandler¹, Efrat Noy², Hanoch Senderowitz², Johannes A. Eble³, Cezary Marcinkiewicz⁴ and Philip Lazarovici^{1,*}

¹ School of Pharmacy, Institute for Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

² Department of Chemistry, Bar Ilan University, Ramat-Gan, Israel

³ Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany

⁴ Department of Bioengineering, College of Engineering, Temple University, Philadelphia, Pennsylvania, USA

Abstract: Snake venoms comprise disintegrins, proteins which target integrin receptor-dependent cell adhesion by endothelial cells. The disintegrins Obtustatin and Viperistatin, were used as lead compounds for the synthesis of linear and cyclic peptides containing the KTS binding motif. The most active linear peptide pointed to the importance of Cys19 and Cys29, and the presence of Arg24 for biological activity, and was used as the basic linear sequence for the synthesis of cyclic peptides. The most potent peptides, named Vimocin and Vidapin, showed a high potency ($IC_{50} = 0.17$ nM) and intermediate efficacy (20% and 40%) in inhibiting adhesion of $\alpha1/\alpha2$ integrin-overexpressing cells to collagen. Vimocin was more active in inhibiting wound healing and corneal micropocket vascularization, whereas Vidapin was more potent in reducing endothelial cell migration in the Matrigel tube assay. Both compounds similarly inhibited proliferation of endothelial cells and angiogenesis induced by vascular endothelial growth factor or glioma tumor cells in the chorioallantoic membrane angiogenic assay. These peptides were well tolerated by mice after intravenous

* **Corresponding author Philip Lazarovici:** Institute for Drug Research School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; Tel: 9727-2-6758729; E-mail: philipl@ekmd.huji.ac.il.

injection. They showed stability in human serum between 10–30 hours. The *in vitro* and *in vivo* potency of these cyclic peptides is consistent with the computational modeling indicating conformational similarities to the parental molecules. Vidapin significantly increased the survival of mice injected with B16 melanoma cells up to 73 days, whereas the median survival time of animals in this tumor experimental model is 40 days. These findings propose that Vimocin and Vidapin can serve as dual $\alpha 1\beta 1/\alpha 2\beta 1$ integrin antagonists in angiogenesis and cancer therapy.

Keywords: Adhesion, Antiangiogenic, Anticancer, Conformation, Cyclic, Disintegrin, Disulfide bond, Endothelial cell, Integrin, KTS motif, Lead compound, Linear, Migration, Molecular dynamic simulations, Molecular modeling, Partial antagonist, Peptides, Peptidomimetic, Proliferation, Stability

30 ANGIOGENESIS

Angiogenesis, the generation of new capillaries, is a complex, still tightly regulated process involving multiple cells, growth factors and extracellular matrix modeling. Angiogenesis occurs by endothelial cells (EC) proliferation and migration leading to capillaries sprouting from the existing microvasculature. Newly formed blood vessels carry oxygen, hormones, nutrients and electrolytes and secrete a variety of growth factors with paracrine and juxtacrine activity on endothelial cells, fibroblasts and pericytes forming the new vasculature [1]. Once these new capillaries have formed and matured, the endothelial cells lining the newly formed blood vessels stop proliferating and become quiescent. Judah Folkman recognized that angiogenesis is crucial for the supported growth of solid tumors [2]. Solid tumors that lack sufficient vascularization become necrotic [3] and/or apoptotic [4] and fail to grow beyond a limited size of 2 mm³, and turning off the “angiogenic switch” is a potential anti-cancer therapy [5]. The tumors that undergo neovascularization enter a phase of rapid growth and exhibit increased metastatic potential [6] since the leaky blood vessels which invade and surround the tumor provide a way for cancer cells to enter the circulation and to metastasize to distinct organs. Thus, many if not all organs may involve cancers in which angiogenesis is an important component. Inhibition of the early steps of angiogenesis has been recognized as an appealing approach for the treatment of human cancers [7]. Angiogenesis inhibition is a promising therapeutic approach,

with very mild side effects, because throughout the body the vasculature is substantially quiescent with very low turnover rate. Therefore, the search for natural antiangiogenic factors and synthetic chemicals may lead to the development of specific antiangiogenic drugs for the supporting therapy of cancer.

2. A1B1 AND A2B1 INTEGRINS ARE TARGETS IN ANGIOGENESIS

Integrins are a family of cell surface receptors which mediate adhesion to multiple ligands and mediate cell-cell and cell-extracellular matrix (ECM) interactions as well as cell signaling. These heterodimeric receptors comprise non-covalently linked distinct subunits, α and β , usually containing a large extracellular binding domain, a transmembrane region, and a short cytoplasmic domain. Upon ligand binding, integrins cluster and recruit *via* their cytoplasmic domains cytoskeletal, adaptor and signaling proteins, thus eventually forming focal adhesions. Focal adhesions anchor the cell to the subjacent extracellular matrix (ECM) ligands, but also convey signals into the cell [8]. From the focal adhesion sites signal pathways diverge and regulate adhesion, migration, proliferation, and survival [9]. Integrins play an important role in the angiogenic process, in physiological as well as in pathological blood vessel formation [10, 11]. Two major collagen binding integrins are $\alpha 1\beta 1$ and $\alpha 2\beta 1$ [8]. The expression of $\alpha 1\beta 1$, $\alpha 2\beta 1$, as well as $\alpha 4\beta 1$, $\alpha 5\beta 1$, $\alpha 6\beta 1$, $\alpha 6\beta 4$, $\alpha 9\beta 1$, $\alpha v\beta 3$ and $\alpha v\beta 5$ endothelial cell integrins is strongly induced by pro-angiogenic growth factors or chemokines [12 - 14]. The $\alpha 1\beta 1$ integrin is abundantly expressed on human endothelium [15] and on lymphocytes which infiltrate the tumor tissue in several solid cancers [16]. Senger *et al.* identified critical cross talk functions for the $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrins not only in EC migration but also in supporting signal transduction by the major angiogenic factor, VEGF [17]. Integrin $\alpha 2\beta 1$ also indirectly regulates angiogenesis by promoting platelet deposition within tumors and damaged tissues [18, 19]. The $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrins directly contribute to mouse mammary carcinoma cell invasion by regulating matrix metalloproteinase-3 (MMP-3) which is involved in extracellular matrix proteolysis [20], a prerequisite for EC migration during the angiogenic process. A key role for $\alpha 2\beta 1$ in angiogenesis was shown by using small molecule, inhibitors of collagen-induced angiogenesis [21]. The importance of $\alpha 1\beta 1$ and $\alpha 2\beta 1$ integrins in tumor angiogenesis was unambiguously

Current Status of Anti-Angiogenic Therapy in the Clinical Management of Lung Cancer

Peter M. Ellis^{1,*} and Abdulaziz Al Farsi^{2,3}

¹ Department of Oncology, McMaster University, Hamilton, Ontario, Canada

² Staff Medical Oncologist, Juravinski Cancer Centre, Hamilton, Ontario, Canada

³ Clinical Research Fellow in Lung Cancer, Department of Oncology, McMaster University, Hamilton, Ontario, Canada

Abstract: Increased angiogenic activity occurs frequently in lung cancer and results in biologically more aggressive disease. There has been intense research into therapeutic agents that inhibit angiogenesis and may improve treatment options for patients with lung cancer. Bevacizumab, a monoclonal antibody directed against serum VEGF, in combination with carboplatin and paclitaxel chemotherapy, has been shown to improve survival for NSCLC patients. Meta-analysis of trials of bevacizumab in combination with platinum-based chemotherapy for NSCLC, show a 10% reduction in the risk of death (HR 0.90, 95%CI 0.81 – 0.99). However, therapy with bevacizumab is limited to NSCLC patients with non-squamous histology, good performance status, no brain metastases and the absence of bleeding or thrombotic disorders. Similar efficacy has been seen also with carboplatin, pemetrexed plus maintenance pemetrexed chemotherapy. In the second-line setting, the addition of ramucirumab to docetaxel chemotherapy, resulted in a modest improvement in survival, adding a second anti-angiogenic treatment option for patients with NSCLC.

A large number of trials in NSCLC have been conducted evaluating oral anti-angiogenic compounds, both in first-line therapy in combination with chemotherapy, or upon disease progression, either as combination, or single agent therapy. Some level of activity has been observed with most agents. No clear improvements in overall survival have been observed, although a subgroup analysis of a trial evaluating the addition of

* Corresponding author Peter M. Ellis: Department of Oncology, McMaster University, Hamilton, Ontario, Canada; Tel: 1 905 387 9495; Fax: 1 905 575 6326; E-mail: ellisp@hhsc.ca.

nintedanib to docetaxel showed improved survival limited to patients with adenocarcinoma. However, these findings require validation. All of the oral anti-angiogenic agents result in added toxicities. Some agents have resulted in an increased risk of death, limiting their development. Currently, there is no established role for anti-angiogenic therapy in SCLC, although there is some promise for sunitinib as maintenance therapy following platinum and etoposide chemotherapy.

Despite the large number of anti-angiogenic agents evaluated in clinical trials, there is evidence supporting a limited number of agents as treatment options for patients with lung cancer. To date no biomarkers have been identified. It is unclear whether treatment effects in a subpopulation, are lost among a larger unselected population of patients. There is a need for additional translational research to identify predictive biomarkers for anti-angiogenic therapy.

Keywords: Angiogenesis, Anti-angiogenic therapy, Chemotherapy, Fibroblast derived growth factor, Monoclonal antibodies, Non small cell lung cancer, Overall survival, Platelet derived growth factor, Progression free survival, Randomized clinical trials, Small cell lung cancer, Tyrosine kinase inhibitors, Vascular endothelial growth factor.

1. ANGIOGENESIS IN THE PATHOGENESIS OF LUNG CANCER

Since its introduction in 1971, the concept of angiogenesis in cancer has gained considerable interest from researchers. Dr. Judah Folkman postulated that tumors need to recruit their own blood supply in order to grow beyond a certain size [1]. This process, named tumor angiogenesis, involves the production of soluble growth factors by the tumor itself. Our understanding of these processes has continued to evolve over time. Angiogenesis is observed in many different cancers including lung cancer [2]. This complex process that depends on many regulatory factors, happens throughout the body. Activating and inhibiting factors regulate angiogenesis and their level of may influence the aggressiveness of cancer [3]. The list of growth factors that induce tumor angiogenesis is long. Understanding their roles resulted in the development and evaluation of multiple therapeutic agents as potential cancer treatments, either alone, or in combination with systemic chemotherapy. Anti-angiogenic therapy provides several benefits including normalizing the abnormal vasculature in cancer, improving delivery of chemotherapy and enhancing its anti-vascular effect and preventing the rapid

repopulation after the systemic treatment [4].




Fig. (1). Vascular endothelial growth factor and angiogenesis [reprinted with permission from A. Hoeben, *et al.* *Pharmacological Reviews* 2004; 56: 549-580].

The most important factors associated with angiogenesis include vascular endothelial growth factor (VEGF) [5, 6], platelet derived growth factor (PDGF) [7] and fibroblast derived growth factor (FGF) [8]. Vascular endothelial cells depend for their survival on serum VEGF (VEGF-A) that stimulates proliferation and migration, inhibits apoptosis and modulates the endothelial permeability [9]. Binding of VEGF to the VEGF receptor (VEGFR-2) triggers a cascade of molecular events that involves phosphoinositide 3-kinase (PI3-kinase) pathway and drives tumor angiogenesis, cell survival and proliferation pathways (Fig. 1) [9 - 11]. Tumors that demonstrate VEGF-A overexpression are associated with a shorter survival [12]. Given this important role in tumor progression, the VEGF/VEGFR-R pathway has been studied extensively as a target for anti-

Angiogenesis in Hepatocellular Carcinoma (HCC) and its Potential Applications in the Development of Anti-HCC Drugs

Guang-Chun Sun^{1,*}, Dai-Wei Zhao², Xu Yang¹ and Lichun Sun^{1,3,4,*}

¹ *Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University; 801 He-Qing Rd., Shanghai 200240, China*

² *Department of Surgery, The Second Affiliated Hospital of Guiyang Medical University; 3 Kang-Fu Rd., Kaili 556000, China*

³ *Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy & Pharmacology, University of South China, Hengyang, 421001, China*

⁴ *Department of Medicine, School of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112-2699, USA*

Abstract: Hepatocellular carcinoma (HCC) is a primary tumor of the liver and one of the most malignant of tumors, with a mortality rate ranked second worldwide. Conventional therapeutics such as liver transplants and surgical resection, are of importance in HCC treatments. However, those treatments are limited and have a high frequency of tumor recurrence and metastasis. Currently, there is only one FDA approved anti-HCC drug - Sorafenib, which is well-tolerated. Thus, there is a great need to develop more effective HCC-targeting drugs. Angiogenesis, with the involvement of various angiogenic and anti-angiogenic factors, is fundamental for tumor growth, invasion and metastasis. HCC is a tumor type having a high level of neo-angiogenesis, and widely varying vascularity during tumor development. The accumulated experimental and clinical data indicate that HCC tumor progression is

* **Corresponding author Lichun Sun:** Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University; 801 He-Qing Rd., Shanghai 200240, China; Tel: 504-988-1179; E-mail: lsun@tulane.edu.

* **Corresponding author Guang-Chun Sun:** Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University; 801 He-Qing Rd., Shanghai 200240, China; Tel: +86-21-24289472; E-mail: sunguangchun@5thhospital.com.

Atta-ur-Rahman & M. Iqbal Choudhary (Eds.)

All rights reserved-© 2016 Bentham Science Publishers

strongly associated with angiogenesis, with poor HCC prognosis related to the increase in micro-vascular density. A series of angiogenic factors have been investigated in HCC and show anti-HCC potential. Presently, there are certain anti-angiogenic therapeutics that have been evaluated in animal models and clinical trials. In this chapter, we will review the advances of HCC angiogenesis, angiogenic factors, the applications of anti-angiogenic agents, and also discuss the limitation, challenge and other potential strategies in searching for anti-HCC drugs via targeting angiogenesis.

Keywords: Angiogenesis, Anti-angiogenesis, Hepatocellular Carcinoma, Sorafenib, Targeting Drugs.

1. INTRODUCTION

With the occurrence of more than one million new cases each year, hepatocellular carcinoma (HCC) became the fifth most common tumor worldwide, and due to its high mortality, is a major global health problem [1]. HCC accounts for 85% - 90% of the primary liver cancers [2], with a 5-year overall survival rate in advanced HCC being less than 10% [3]. According to statistics, HCC caused 696,000 deaths worldwide in 2008 [4]. The occurrence of cases has distinct geographical variation, with the vast majority of cases (85%) occurring in developing countries, especially in Asia and sub-Saharan Africa. Lower rates are in Australia, Northern Europe, and the US [5]. China alone accounts for more than 50% of all cases worldwide [2] even though a decline in the incidence rate has been observed in Hong Kong and Shanghai. The main reason for this phenomenon is the high prevalence of hepatitis B virus (HBV) infection there. Most HCC cases (approximately 80%) are related to an infection of chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) [6], in which most patients also have cirrhosis [6]. Chronic liver injury at the cirrhosis stage promotes steato-hepatitis [2]. In addition, cirrhosis is present in the majority of HCC patients [7, 8].

In the prevalent areas, most HBV cases are transmitted through vertical and early horizontal transmission. Therefore, HBV vaccination given to newborns may dramatically reduce HBV infection in early life and decrease HCC cases in the future. However, the number of HCC cases increases in Europe and North America as the incidence of HCV infection and alcoholic cirrhosis rises [9, 10]. HCC mortality has nearly doubled during the period from 1975 to 1995 [9, 11]. In the coming years, a steady increase is predicted for the incidence of HCC because

of an increasing prevalence of non-alcoholic steato-hepatitis caused by obesity and metabolic syndrome [12].

Traditional HCC treatments, including resection, liver transplantation, percutaneous ethanol injection (PEI), radiofrequency ablation (RF) and transcatheter arterial chemoembolization (TACE), are only possible for HCC patients who are diagnosed with small tumor burdens [13]. As for conventional chemotherapy, there is limited efficacy for HCC patients, and currently there is no standard treatment for patients with non-resectable HCC [13, 14]. In addition, HCC prognosis is poor [15]. Patients with HCC and accompanied liver cirrhosis have a 2-year survival rate of 82%. Most patients with advanced cirrhosis have less than 32% of their 2-year survival rate [15, 16]. Therefore, there is an urgent need to develop a systemic and effective intervention therapy, especially for patients with advanced HCC. This is due to HCC being asymptomatic in the early stages and limited surveillance results in this disease eventually being diagnosed at an advanced stage. Innovative strategies, such as targeting the non-transformed, less resistant, tumor-supporting endothelial cells, are needed [17].

Currently, there are only a limited number of drugs as potential options for HCC treatment. There are several clinical trials under investigation [18]. To date, Sorafenib, a small-molecule kinase inhibitor, is the only FDA-approved drug for patients with advanced HCC. It has only modest effectiveness at prolonging patients' overall survival (OS) for 2-3 months [19]. The mechanism modulated by Sorafenib is not well known. Also, there is no unique biomarker to predict the effectiveness of Sorafenib. The tolerance and resistance seen in some HCC patients further limits the clinical efficacy of Sorafenib.

For both prevention and treatment, the strategies in recent years seemingly shift from broad disease-based treatments to specific therapies targeting aberrant cellular signaling pathways [18]. HCC is a tumor type with high levels of neo-angiogenesis and vascularity [20]. Angiogenesis is of importance for HCC progression and metastasis. Notably, the vascular vessels originate from hepatic arteries, but not the portal vein [20]. Arteriogenesis is defined as the growth of functional collateral arteries covered with smooth muscle cells from pre-existing arteries [21]. The increased arteriogenesis was seen in HCC by testing arterial

Bevacizumab for Glioblastoma Treatment: Reviewing Biological and Clinical Hypothesis for its Success and Failures

Ana C. Fernandes^{1,#}, Cláudia Caeiro^{1,#}, Vera Miranda-Gonçalves^{2,3}, Fernanda Cury⁴, Margarida Damasceno¹, Rui M. Reis^{2,3,4} and Olga Martinho^{2,3,4,*}

¹ *Department of Oncology, Centro Hospitalar S. João, Porto, Portugal*

² *Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal*

³ *ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal*

⁴ *Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil*

Abstract: Glioblastoma multiforme (GBM) is the most aggressive malignant primary brain tumor in adults with a very poor prognosis. The standard treatment for newly diagnosed glioblastoma is surgical debulking followed by radiotherapy and temozolomide (TMZ) with additional maintenance with TMZ. However, this regimen offers modest benefits with a median survival of less than 15 months, with an inevitable recurrence.

GBM is one of the most vascularized tumors; therefore antiangiogenic therapeutic strategies are very appealing. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, was the first FDA approved angiogenesis inhibitor, based on impressive response rates in recurrent GBM. Recent trials have shown that the combination of bevacizumab with standard radiotherapy–TMZ for the treatment of newly diagnosed glioblastoma resulted in improved median progression-free survival, without gain in overall survival. Data regarding quality of life and functional status are conflicting. Not surprisingly, there was an increase in adverse

* **Corresponding author Olga Martinho:** Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; Tel/Fax: +351253604868; E-mail: olgamartinho@eceaude.uminho.pt.

These two authors contributed equally to the work

events associated with bevacizumab therapy, namely thrombosis, bleeding and hypertension. Therefore, the efficacy of antiangiogenic therapy in the management of GBM remains unclear. To improve outcomes, it has been made a huge effort to better understand the biology underlying angiogenesis and tumor survival, as well as the mechanisms of antiangiogenic resistance in GBM.

Keywords: Angiogenesis, Antiangiogenic, Bevacizumab, Biomarkers, Central nervous system, Glioblastoma, Glioma, Quality of life, Resistance, Response, Safety, Survival, VEGF.

1. INTRODUCTION

Primary central nervous system (CNS) tumors constitute the leading cause of cancer-related death in the pediatric population and the fourth in middle-age men, while accounting for less than 2% of all malignancies. Gliomas are the most common CNS tumors, representing approximately 70% of all brain tumors. Astrocytomas are the most frequent gliomas and are divided into four grades of malignancy. The World Health Organization (WHO) classifies them on the basis of histologic features into four prognostic grades: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma). Grade III and IV tumors are considered high-grade gliomas presenting increased cellularity, nuclear atypia, and mitotic activity and glioblastomas also contain areas of microvascular proliferation, necrosis, or both [1 - 3].

Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the most common and aggressive malignant primary brain tumor in adults. Standard treatment consists of maximal surgical resection followed by radiotherapy (RT) plus concomitant and adjuvant TMZ [4]. However, this regimen offers modest benefits with a median overall survival (OS) of only 14–15 months [5]. When relapse or progression occurs, there is no standard treatment and OS ranges from 3 to 9 months [6]. Despite advances in conventional treatment, the outcome remains almost universally fatal. Therefore, a better understanding of glioblastoma biology and more effective therapeutic options are warranted.

Primary GBM, responsible for 90% of glioblastoma cases, typically occurs in

patients older than 50 years of age and is characterized by EGFR (epidermal growth factor receptor) amplification and mutations, loss of heterozygosity of chromosome 10q, PTEN deletion or mutations, and p16 deletion, in addition to *TERT* promoter mutations. Secondary GBM is manifested in younger patients as diffuse or anaplastic astrocytoma, which transforms over a period of several years into glioblastoma. It is characterized by mutations in the *TP53* tumor suppressor gene, overexpression of the PDGFR (platelet derived growth factor receptor), abnormalities in the p16 and retinoblastoma (Rb) pathways, loss of heterozygosity of chromosome 10q and, *IDH1* or *IDH2* mutations [1, 7 - 11].

During embryogenesis, the development of the vasculature involves the birth of new endothelial cells and their assembly into tubes (vasculogenesis) in addition to the sprouting (angiogenesis) of new vessels from existing ones. Following this morphogenesis, the normal vasculature becomes largely quiescent. In the adult, as part of physiologic processes, such as wound healing and female reproductive cycling, angiogenesis is turned on, but only transiently. In contrast, during tumor progression, an “angiogenic switch” is almost always activated and remains on, causing normally quiescent vasculature to continually sprout new vessels that help sustain expanding neoplastic growths [12]. This “angiogenic switch” is mediated by the release of a wide array of proangiogenic factors, mainly vascular endothelial growth factor (VEGF), and by endothelial, stromal, and tumor cells, which cause vessel growth and tumor expansion [12]. VEGF consists of a family of 5 glycoproteins named VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor. They bind with their corresponding tyrosine kinase receptors (VEGFR1, VEGFR2, and VEGFR3), activating a downstream signal that results in the development of angiogenesis, increased vascular permeability, and lymphangiogenesis. Of the 5 glycoproteins, VEGFA plays the most important role in tumor angiogenesis, as elevated levels in patients with cancer, specifically breast, lung, colon, uterus, and ovary cancers, confer a worse prognosis [13, 14].

Given that GBM is one of the most vascularized human tumors, it is not surprising that GBM cells produce a wide variety of proangiogenic factors, including VEGF. Tumor vessels in GBMs are disorganized, highly permeable and present abnormal endothelial walls, different from normal blood vessels morphologically and functionally [15, 16]. Angiogenesis is induced by

SUBJECT INDEX

- A**
- Acne 33, 35, 60, 61, 62, 63, 64, 65, 66, 67, 68, 72, 73, 75, 77, 78, 79, 80, 81, 100, 102, 107, 170, 224, 226
 - adverse effects of 60, 61
 - burden of 66, 68
 - facial 62, 67
 - impact of 74, 75
 - psychological effects of 60, 61
 - Acne Disability Index (ADI) 75
 - Acne excorree 100, 104, 107, 109
 - Acne lesions, visible 62
 - Acne patients 67, 68, 70, 71, 72, 73, 78
 - Acne severity 64, 73
 - Acne symptoms 75
 - Acne treatment, effective 68
 - Adalimumab 37, 39, 42, 43, 146
 - Addressing Distress 155
 - Adjunctive treatment 152
 - Adolescence 60, 61, 62, 64, 65, 68, 81
 - Adolescent psychiatric unit 89
 - Adolescent psychiatry 90
 - Adolescents 62, 63, 64, 65, 68, 70, 170, 174, 175, 177, 178
 - Alcohol consumption in psoriatic patients 40
 - Alcohol exacerbates psoriasis severity and pruritus 147
 - Alcoholic patients anti-psoriatic treatment 41
 - Alcohol intake in psoriasis 41
 - Alexithymia 135, 136, 138
 - Alopecia areata 35, 66, 197, 198, 202, 214
 - Analysand 189
 - Anti-androgen treatment 108
 - Anti-depressant 136, 149
 - Antipsychotic medications 119, 126, 127, 128, 129, 130
 - effective 119, 130
 - traditional 130
 - Anti-psychotic medication therapies 126
 - Antipsychotics 126, 127, 228
 - Anti-psychotics 118
 - Anxiety 25, 26, 28, 31, 32, 33, 34, 35, 36, 37, 38, 41, 42, 43, 60, 65, 66, 67, 68, 69, 70, 71, 76, 77, 78, 79, 80, 81, 94, 100, 101, 103, 106, 108, 109, 115, 119, 122, 129, 135, 136, 147, 148, 149, 150, 151, 152, 153, 168, 171, 172, 176, 195, 197, 202, 207, 210, 216, 224, 225, 227, 229
 - assessed 71
 - associated 109
 - existential 65
 - general 66
 - improved 33, 34
 - increased 171
 - interpersonal 35, 37
 - social-evaluative 77
 - state 227
 - Anxiety depression score 154
 - Anxiety-provoking situations 80
 - Anxiety scores 150
 - Anxiety symptoms 67, 69, 76
 - Appendixes 201
 - Approach 186, 190, 217
 - psychoanalytic 190
 - psychodynamic 186, 217
 - psychosomatic 190, 198

- Assessment 60, 75, 77, 96, 100, 140, 176, 200
 psychometric 75
Assessment of psychosocial morbidities 104
Assessment of quality of life impact and distress 154
Atopic dermatitis 9, 10, 13, 25, 31, 33, 35, 37, 66, 72, 198, 224, 226
Atopic dermatitis patients 13
Atopic eczema 169, 171, 172, 174, 175, 176, 178
Atypical antipsychotics 126, 128, 129
 safer 126
Autogenic training 81, 175
- B**
- BDD, incidence of 92, 93
BDD-patients benefit 96
BDD symptoms 70, 93, 95
BDD treatment 94, 95
Biological agents 34
Biological treatments 34, 37, 39, 42
Body Image disturbance questionnaire (BIDQ) 76
Body mass index (BMI) 89, 147
Boehringer Ingelheim 44
Brain-derived nerve factor (BDNF) 9
- C**
- Calcitonin-gene related peptide (CGRP) 5, 7, 8, 10, 27
Cardiff acne disability index (CADI) 75
Cardio-vascular disease (CVD) 143
Care 43, 63, 89, 96, 100, 119, 124, 135, 136, 137, 158, 172, 176, 179, 223, 228
 daily skin 172
 effective patient-centred 158
 integrative patient 223
 local skin 228
 psychological 179
Catecholamines 5, 7, 8, 10, 11
Cells 3, 4, 6, 7, 8, 9, 10, 11, 27, 28, 214
 glandular 7, 9
 immune 6, 7, 8
 mast 4, 6, 9, 27
Central nervous system (CNS) 3, 122, 171
Child psychiatrist 109
Child psychiatry 89
Children and adolescents 170, 174, 175, 177, 178
Children psychoanalysis 190
Children's dermatology life quality index (CDLQI) 173
Chromogranin 6
Chronic immune-mediated genetic disease 25
Chronic skin conditions 37, 167, 168, 169, 170, 172, 173, 174, 175, 178
Chronic skin diseases questionnaire 174
Clinic 65, 104, 124, 135, 136, 153, 154, 223, 224, 225, 226, 228
 joint psycho-dermatology 104
 psychodermatological 223
 quality of life impact and distress in 135, 154
 specialist acne 65
Clinical psychology 156
Cognitive behavioral 176, 177

- treatments 176, 177
- Cognitive -behavior therapy (CBT) 42, 80, 88, 95, 96, 106, 109, 115, 136, 152, 153
- Communication of patient goals 158
- Co-morbidities, concomitant psoriasis 143
- Comorbidities, psychological 60, 62, 73
- Component, strong psychological 110
- Concomitant psychological/psychiatric input 108
- Condition, psychodermatologic 119
- Conflicts and Patient's Motivation 211
- Consultation 113, 135
 - patient-centred 135
 - psychiatric 113
 - skin-focused 135
- Conversion disorder patients 206
- Convoy therapeutics 44
- Coping strategies 67, 78, 139, 141, 153, 174, 179, 211
- Corticotropin-releasing hormone (CRH) 5, 11, 27, 28
- Cutaneous dysesthesia 103, 123
- Cutaneous lesions 10
- Cyclosporine 41
- D**
- Defective adrenergic response 27, 28
- Defence mechanisms 186, 200, 211, 217
- Degree of awareness of psychological suffering 194
- Delusional infestation 103, 113, 118, 119, 130, 170, 178, 179, 225, 226, 227, 228, 229
- skin features 113
- Delusional patient's symptoms 124
- Delusions 118, 120, 122, 125, 128, 179
 - parasite 227
- Depressed patients 36
- Depression 25, 30, 31, 35, 36, 37, 38, 41, 42, 43, 60, 62, 66, 67, 68, 69, 70, 71, 76, 77, 78, 82, 88, 93, 94, 95, 96, 101, 102, 103, 104, 106, 108, 109, 115, 122, 135, 136, 137, 138, 148, 149, 150, 153, 155, 175, 176, 195, 197, 223, 224, 225, 227
 - associated 106
 - improved 43
 - major 62
 - untreated 95
- Depression scale 76, 229
- Depression score 42, 146, 152
- Depressive disorders 35, 65, 66, 71, 74, 109
 - major 35, 71
 - persistent 35
 - possible 74
 - substance/medication-induced 35, 71
 - unspecified 71
- Depressive symptoms 35, 71, 73, 76, 94, 127
- Dermatological conditions, primary 112, 113
- Dermatological consultation 179
- Dermatological diseases 13, 25, 41
- Dermatological interventions 173
- Dermatological outpatients range 224
- Dermatological practice 167, 174, 178, 179
- Dermatological treatments 167, 168, 173, 176, 217

- regular 167, 168, 176
- Dermatologic disease 123, 196, 197
 - primary 123
- Dermatologic treatments, traditional 193
- Dermatology clinics 93, 104, 110, 136, 223, 226
 - common 226
 - dedicated psycho 104
 - general 110
 - ordinary 223, 226
- Dermatology life quality index (DLQI) 29, 73, 74, 104, 136, 146, 154, 158, 173, 213, 229
- Dermatology setting 110, 115, 224
 - dedicated psycho 115
 - outpatient 224
 - specialist psycho 110
- Diagnose psychocutaneous disease 224
- Diagnosis 197, 200
 - dermatologic 200
 - psychoanalytic 197
 - somatic disease 197
- Diagnostic criteria 93, 94
- Disease 6, 26, 29, 30, 31, 35, 36, 38, 40, 41, 60, 62, 63, 67, 74, 77, 82, 89, 91, 104, 119, 121, 126, 127, 136, 154, 173, 176, 186, 187, 193, 194, 199, 200, 202, 204, 207, 209, 211, 212, 214, 216, 217, 218, 225, 229
 - cardiac 31, 127
 - cardiovascular 38, 41
 - life-threatening 60, 62
 - organic 204
 - psycho-cutaneous 40
 - psychosomatic 187
- Disease severity 33, 36, 146, 171, 175, 176
 - decreased 176
 - reduced 175
 - reported reduced 175, 176
- Diseases severity 175
- Disfiguring disease 26, 31
- Disorder 3, 60, 61, 62, 69, 70, 71, 88, 89, 91, 92, 94, 100, 101, 102, 109, 110, 112, 115, 118, 119, 122, 127, 178, 179, 186, 204, 214, 215, 217
 - dermatological 62, 186, 204, 217
 - eating 89, 91, 92, 94, 112
 - factitious 100, 110, 178, 179
 - minor 60, 61
 - neurologic 127
 - obsessive-compulsive 60, 69, 71, 115, 122
 - psychodermatologic 118
- Distress 9, 32, 40, 41, 42, 43, 68, 71, 76, 77, 80, 92, 93, 94, 135, 136, 139, 141, 144, 146, 148, 149, 152, 153, 154, 155, 170, 189
 - discussed 153
 - financial 32
 - high levels of 93, 144
 - identifying 154
 - psychiatric 9
 - psychological 41, 42, 68, 144, 152, 170
 - reducing psychosocial 80
 - relieve 43
- Distress improve psoriasis 149
 - strong 118
- Drugs, psychotropic 9
- DSM diagnosis of generalized anxiety and subjective stress 33

- Dysmorphophobia 13, 88, 90, 91
- E**
- Early/naive psychodermatology
platforms 226
- Effects 31, 43, 228
anti-anxiety 43
antidepressive 228
direct 31
- Effects of psychological interventions
196
- Ego functions 197, 198
- Emollients patient preference 105
- Emotional distress 13, 60, 64, 66, 68,
72, 76, 110, 151
significant 72
- Emotional expression 186, 214, 218
- Emotions 10, 68, 75, 100, 135, 137,
138, 139, 155, 158, 186, 188, 189,
200, 203, 210, 214, 215, 217, 218
- Endorphins 5, 7
- Enkephalins 5
- Epidemiologic studies depression scale
76
- Epinephrine 5, 7, 8
- Epiphenomenon 40, 41
- Erectile dysfunction 37, 38, 39, 144
- Escitalopram 43, 150
- Exacerbate 62, 63, 65, 80, 100, 155
- Exacerbations 25, 26, 27, 150
stress-induced 27
- Excoriation disorder 60, 71
- Excoriations, psychogenic 13
- Extrapyramidal side effect 126, 127,
128, 129
- F**
- Factors 6, 25, 27, 33, 36, 37, 38, 63, 64,
65, 104, 106, 113, 153, 173, 174,
175, 186, 189, 193, 196, 211, 212
behavioral 174
external stress 36
nerve growth 6, 27
psychopathologic 211
skin-related 175
stress-related 175
unconscious 186, 189, 212
- Fibroblasts 7
- First-generation anti-psychotics 128
- Fluoxetine 43, 106, 109
- Formications 123, 128
- G**
- Gastrin-releasing peptide (GRP) 5, 7
- Generalized anxiety 33
- General practitioner (GP) 94, 135, 136,
155
- Genital psoriasis involvement 39
- Guide treatment decisions 135
- H**
- Hamilton anxiety rating scale 227
- Health related quality of life (HRQoL)
62, 104
- Hospital and anxiety depression score
154
- Hospital anxiety and depression scale
(HADS) 71, 76, 146, 154, 158,
227
- HPA axis 11, 27

- Humoral level 209
 Hyperprolactinemia 129, 130
 Hyper-sensitive reaction 207
 Hypnosis 42, 136, 151
 Hypnosis and biofeedback 42
 Hypothalamic-pituitary-adrenal (HPA) 11, 26
- I**
- Immune systems 8, 27, 40, 42, 171, 207
 Infections, secondary skin 123
 Inflammation, modulate skin 6
 Inflammatory activity, chronic skin-related 171
 Inform treatment goals 135
 Initiating treatment 126
 Insight psychotherapy 193
 Internalisation 138, 139
 International psoriasis foundation 40
 International psychoanalytical association (IPA) 189
 Interpersonal relationships 32, 35, 37, 63, 170
 Interventions 78, 175, 176, 178, 180
 intensive psychodermatology 78
 multimodal 175, 176, 178
 potent dermatologic 78
 psychopharmacological 180
 stress-management 175
 Isotretinoin, oral 78
 Issues, negative psychological 63
 Itching cognitions questionnaire (ICQ) 174
- K**
- Keratinocyte(s) 4, 6, 7, 8, 9, 10, 40, 214
 proliferation 8, 40
- L**
- Langerhans cells 4, 6, 7, 8, 27
 Level of psychological/psychiatric 186, 217
 Lichenified skin 10
 Life impact of psoriasis in clinic 153
 Lymphocytes 6, 7, 9, 201
- M**
- Macroscopic psychiatric/psychological viewpoint 200
 Magdalena 187
 Mediators 11, 12, 35, 36, 37
 common inflammatory 35, 36, 37
 Medical treatments of skin conditions 169
 Medications 25, 41, 43, 78, 88, 90, 95, 118, 124, 126, 127, 128, 129, 137, 150, 194, 196, 197, 225
 anti-anxiety 43
 atypical antipsychotic 127
 effective psychodermatologic 124
 psychiatric 194, 225
 psychotropic 78, 126, 150
 second-generation anti-psychotic 118

- Melanocytes 4, 6, 7, 10, 206
Melanocyte-stimulating hormone (MSH) 5, 7
Mental disorders 13, 33, 91, 122, 198
Mental health 30, 31, 62, 204
Merkel cells 4, 6, 7
Mild anxiety 33
Mild-moderate depression 43
Mild pruritus 29, 30, 34, 36
Mirtazipine 106, 109
Models, biopsychosocial 60, 63
Monoclonal antibody 34, 37, 39, 42, 43
Montgomery åsberg depression rating scale 227
Morgellons disease 120
Multidisciplinary group treatment 177, 178
 short-term 178
Multifactorial disorder 60, 61
Multimodal treatments 167, 174
Muscle cells 7, 9
- N**
- Negative psychological effects 63
Negative thoughts 80
Nerve fibers 3, 4, 8, 9, 10
Nerve growth factor (NGF) 6, 9, 27
Nervous system 3, 7, 9, 10, 11, 26, 27
 sympathetic 26, 27
Neurokinins 5
 A (NKA) 5
 B (NKB) 5
Neuromediators 5, 6, 7, 8, 9, 10, 11
Neuronal enolase 6, 7
Neuropeptides 5, 6, 27, 201
Neurotensin 5, 11
Neurotic organizations 196, 199
Neurotransmitters 3, 5, 6, 8, 9, 10, 11, 12, 27
 ancient skin 5
Neurotrophins 9, 27
Nongenital skin sites 205
Nonpharmacologic treatments 193
Non-stress responders 26
Norepinephrine 5, 7, 28
- O**
- Objectives specifically designed for skin patients 215
Obsessive compulsive disorder 88, 91, 100, 102, 108, 122
Obsessive-compulsive disorder (OCD) 60, 69, 71, 91, 92, 93, 102, 103, 106, 108, 115, 122
Oral antibiotics 78, 108
Organizations 199, 228
 comprehensive structural 199
 legal authorities/patients 228
- P**
- Palmoplantar psoriasis 30
Parasitosis 71, 118, 119, 122
Paroxetine 43
PASI scores 146, 150, 151, 152, 154
PASI scoring system 154
Pathological skin 101
Patient centred consultation 156
Patient-centred consultation styles 158
Patient health questionnaire 76
Patient's illness perceptions 31
Patient's Motivation 211

- Patients relapse 129
- Patient's symptoms 125
- Peptide histidine isoleucine (PHI) 5
- Peter's psoriasis 187
- Phantasies 192, 205
- Phototherapy 42, 105, 146, 150, 151, 168
- Phototherapy treatment 148
- Physical component summary (PCS) 73
- Physical conditions, chronic 172
- Pilosebaceous units 60, 61
- Population, non-psoriasis 39
- Post traumatic stress disorder 108
- Prognosis 81, 106, 109, 115
- Prolactin 5, 127
- Pro-opiomelanocortin 7, 11
- Protein gene product (PGP) 6, 7
- Psoriasis 25, 26, 29, 32, 34, 36, 38, 39, 42, 136, 145, 147, 148, 150, 158
 - childhood 145
 - developing 39
 - drive 147
 - early-onset 29, 36, 39
 - exacerbate 148
 - exacerbated 150
 - exacerbates 26
 - genital 38
 - gentleman's 136
 - improving 42
 - late-onset 36
 - long standing 29
 - managing 158
 - moderate 38
 - moderate/severe 150
 - personality trait 25
 - pustular 30, 39
 - sexual dysfunction in 32, 39
 - to-severe 34
- Psoriasis alexithymia 138
- Psoriasis and eczema 168, 177
- Psoriasis area severity index (PASI) 26, 136, 140, 150
- Psoriasis centre 153, 212
 - specialist 153
- Psoriasis clearance 150, 152
- Psoriasis complain 32
- Psoriasis disability index 29
- Psoriasis index of quality of life 29
- Psoriasis lesions 9, 38
- Psoriasis life stress inventory 29
- Psoriasis patients 9, 28, 29, 30, 33, 34, 35, 41, 42, 43, 187, 188, 205
- Psoriasis plaques 152, 211
- Psoriasis quality of life 29
- Psoriasis-related work productivity and activity impairment 146
- Psoriasis report feeling 139
- Psoriasis severity 144, 146, 151, 152
- Psoriasis-stress relationship 43
- Psoriasis- stress relationship 26
- Psoriasis symptoms 9
- Psoriasis therapy 42
- Psoriatic 28, 37
- Psoriatic arthritis 30, 33, 36, 38, 143
- Psoriatic arthritis patients 34
- Psoriatic lesions 26, 27, 28, 30, 32
- Psoriatic plaques in high stress group 27
- Psoriatic skin 10, 28
- Psychiatric assessment 104
- Psychiatric background 37
- Psychiatric comorbidities 43, 74
- Psychiatric conditions 88, 103, 198

- Psychiatric diagnoses 108, 122, 127, 197, 200
 comorbid 122, 127
- Psychiatric diseases 41, 122, 225
 leading primary 225
 possible comorbid 122
- Psychiatric disorders 9, 69, 71, 107, 113, 122, 193, 194, 198, 223, 224, 225
 primary 198, 225
 secondary 71
- Psychiatric etiology 118, 119
- Psychiatric evaluation 104
- Psychiatric Interventions 106, 108, 196, 224
- Psychiatric morbidity 41, 224
- Psychiatric nature 115, 170
- Psychiatric problems 167, 174, 178, 179
- Psychiatric/psychological problems 115
- Psychiatric/Psychosocial Interventions 115
- Psychiatric referrals 118, 119, 225
- Psychiatric symptoms 107, 197
- Psychic development 193
- Psychic predicament 193
- Psychic skin 197
- Psychic structures 204
- Psychoanalysis 186, 187, 188, 189, 190, 196, 198, 211, 215, 218
 orthodox 190
 post-Freudian 190
 skin in 187
- Psychoanalysis functions 196
- Psychoanalysis stresses 192
- Psychoanalyst 186, 187, 188, 191, 194, 196, 197, 199, 212, 213, 216
 trained 196
- Psychoanalytic 200
- Psychoanalytical conception 186, 191, 217
- Psychoanalytical theory 202
- Psychoanalytical treatments 195
- Psychoanalytic contributions 193
- Psychoanalytic evaluation 186, 217
- Psychoanalytic perspective 217
- Psychoanalytic schools 188
- Psychoanalytic statements 190
- Psychoanalytic terms 211
- Psychoanalytic theory 190
- Psychoanalytic treatment 189, 196
 intensive 189
- Psychocutaneous disorders 13, 224
- Psychodermatological approach 178, 180
 multidisciplinary 178
- Psycho dermatological conditions patients 104
- Psychodermatological disorders 186, 217, 223, 225
 common 225
 diagnosing 223
 primary 225
- Psychodermatologic literature 128
- Psychodermatologic therapies 125
- Psychodermatologist 198, 200, 216
- Psychodermatology care 226
- Psychodermatology clinics, regional 225
- Psychodermatology multidisciplinary team 225
- Psychogenic dysesthesia 13
- Psychogenic/Neurotic excoriation 101
- Psychogenic pruritus 13

- Psychogenic skin sensation 13
- Psychological approaches 43, 115
- Psychological assessment 60, 173
- Psychological burden, significant 66
- Psychological consequences 68, 211
- Psychological defences 191
- Psychological disorders 13, 62
- Psychological distress benefit 168
- Psychological factors 10, 13, 36, 66, 136, 137, 168, 224
- Psychological factors in people 135
- Psychological factors in psoriasis 37
- Psychological general well-being index 29
- Psychological healing 213
- Psychological impairment 37
- Psychological intervention 60
- Psychological interventions 78, 149, 150, 171, 176, 179
 - web-based 42, 152
- Psychological interviews 196
- Psychological problems 63, 66, 80, 139, 144, 188, 191
- Psychological processes 63
- Psychological terms 206
- Psychological testing 75
- Psychological treatments of skin diseases 180
- Psychological variables and stressful life events 193
- Psychological well-being 31, 141, 167, 168, 172
 - decreased 167, 168
- Psychologic cause 120
- Psychologic interventions 196
- Psychologische behandelung 180
- Psychometric tools 74
- Psychopathology 63, 75, 178
- Psycho-pharmacological treatments 70
- Psychosis 127, 197, 210
- Psychosis and spaces of reciprocal inclusions 209
- Psychosocial 74, 77, 113, 174, 196, 211
- Psychosocial burden 43, 67
- Psychosocial consequences 60, 62, 179, 193
 - adverse 60, 62
 - potential 179
- Psychosocial counselor 173
- Psychosocial development 63, 170
- Psychosocial element 110
- Psychosocial factors 60, 167, 168, 171
- Psychosocial impact 62, 77
 - marked 62
- Psychosocial impairment 77
- Psychosocial implications 62
- Psychosocial morbidities 104
- Psychosocial outcome measures 73
- Psychosocial problems 63, 173
 - skin-related 167, 174, 175
 - target 175
- Psychosocial situation 213
- Psychosocial stress exacerbates psoriasis 26
- Psychosocial stressors 102, 106, 112, 175, 199
- Psychosocial symptoms 173
- Psychosocial well-being 30, 168
 - decreased 168
- Psychosomatic chain 211
- Psycho-somatic dissociation 195
- Psychosomatic problem 190
- Psycho therapist 195

- Psychotherapy 9, 42, 43, 113, 186, 190, 193, 195, 196, 207, 211, 212, 213, 214, 216, 217, 218, 228
dynamic 228
psychoanalytic 190, 218
psychodynamic 213
Psychotherapy aims 217
Psychotherapy and cognitive behaviour therapy 115
Psychotherapy outstands 211
Psychotherapy sessions 152, 195
individual 152
Psychotherapy treatment 194
Psychotic 197
Psychotic disorders 40, 126, 128
Psychotic elaboration 210
Psychotic levels 200
Psychotic organizations 196, 199, 210
Psychotic regression 203
- Q**
- QoL instruments 29
QT prolongation 127, 128
Quality of life instruments for psoriasis 29
Quetiapine 127, 128, 129
- R**
- Relaxation exercises 167, 174, 175, 177
Relaxation therapy 42, 176
Relaxation training 81, 152
Risperidone 115, 127, 128, 129, 228
Rosenberg self-esteem scale (RSES) 77
- S**
- Salford psoriasis Index 29
Schizophrenia 88, 122, 126, 129
Screening for BDD in acne patients 70
Screening Question 94
Second generation antipsychotics (SGAs) 128, 129, 130
Selected Antipsychotic Medications 127
Selective serotonin reuptake inhibitors (SSRI) 43, 88, 95, 96, 106, 109, 115, 127, 128
Serotonine reuptake inhibitors 88
Serotonin pathways 115
Service 153, 155
dedicated psychology 153
local psychology 155
psychology-based
psycho-dermatology 155
Sexual dysfunction 25, 30, 36, 37, 38, 39, 129
Short-term stress management training 175
Side effect profile of antipsychotic medications 127
Side effects 128, 129, 212
patients experience extrapyramidal 128
Simplified psoriasis index (SPI) 140, 154
Skills 32, 67, 177
psychological 32
social 67, 177, 197
Skin 10, 28, 72, 111, 158, 197

- defensive 197
- facial 89
- involved 28
- normal 111
- red 177
- second 192, 197
- sensitive 10
- standard 158
- unblemished 72
- wounded 170
- Skin aging 13
- Skin alcohol 40
- Skin and mental disorders 13
- Skin barrier function 104
- Skin biopsies 104
- Skin blemishes 72
- Skin care routines 177
- Skin cells 6, 11, 201
- Skin changes 118, 123, 124
 - secondary 123
- Skin complaints 170, 177
 - improving 177
- Skin condition(s) 63, 65, 66, 67, 72, 74, 77, 80, 81, 107, 113, 144, 145, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 179, 192, 197, 223, 224
 - disfiguring 63, 145
 - impact of 168, 224
 - inflicted 107
 - prevalent chronic 168
 - visibility of 169, 172
- Skin conditions experience 167, 168
- Skin conditions report 170
 - chronic 169
- Skin container function 197
 - failed 192
- Skin cultures 113
- Skin damage 169, 172, 173
- Skin debris 121
- Skin deterioration 177
- Skindex-61 29
- Skin disease 3, 72, 75, 81, 100, 103, 108, 110, 111, 113, 115, 169, 171, 173, 176, 177, 180, 187, 191, 193, 194, 195, 196, 217, 224, 225
 - artefactual 110, 225, 227
 - chronic 62, 173
 - chronic inflammatory 171
 - depression-worsened inflammatory 227
 - factitious 111
 - granulomatous 113
 - multifactorial 198
 - real 192
 - visible 61, 64
- Skin disorders 8, 9, 10, 11, 13, 190, 193, 194, 195, 197, 225
 - associated 225
 - common 224
 - common primary 113
 - factitious 110
 - inflammatory 3
 - primary 100
- Skin exposure time 157
- Skin flakes 121
- Skin flare mediating fibres 12
- Skin functions 3, 191
- Skin handling 223
- Skin involvement 33
- Skin issues 105
- Skin lesions 13, 110, 113, 178, 203, 206, 215, 229
 - inflicted 110

- psychosomatic 206
 - self-inflicted 178
 - Skin modifications 192
 - Skin neuromediators 6
 - Skin neurons 4
 - Skin problems, pre-existing 102
 - Skin production 11
 - Skin-related illness cognitions 174
 - Skin-related problems 177, 179
 - Skin rubbing 71
 - Skin swabs for microscopy and culture 104
 - Skin therapy 114
 - Sleep problems 169, 170
 - Smoking and alcohol 146, 147
 - Smoking exacerbates psoriasis 39
 - Social anxiety disorder 69
 - Social disruption 144
 - Social life 33, 76, 135, 136, 137, 154
 - Social problems 168, 170, 179
 - Social situations provoke anxiety 69
 - Social support 63, 67, 79, 174
 - Social worker 223, 226, 227, 228
 - Somatic condition, real 186, 217
 - Somatic conditions 171, 187
 - Somatic disease 204, 205, 210, 229
 - Somatic trait anxiety 29
 - Specimens 121
 - SPS-Skin Picking Scale 104
 - States, dissociative 110
 - Stigmatization, perceived 171, 175, 176
 - Stigmatization patients 32
 - Stress 11, 25, 26, 30, 42, 63, 100, 171, disease-related 176 psoriasis-related 42 psychological 11, 30, 63 psychosocial 25, 26, 100 skin conditions cause 171
 - Stress and psoriasis 148
 - Stressful situations 106, 148, 171
 - Stress management 152, 168, 176
 - Stress-management 176
 - Stress management trainings 171
 - Stress-psoriasis association 27
 - Stress-responders, non-depressed 43
 - Suggested investigations for skin picking disorder 104
 - Suicide ideation 60, 69
 - Suicide risk contact liaison psychiatrist 155
 - Support group, psychotherapeutic 150
 - Sympathetic nervous system (SNS) 26, 27
 - Syndromes, anxious-depressive 193
 - Systems, neuro-immuno-cutaneous 3, 8
- T**
- Team 100, 175, 200, 223, 227 interdisciplinary 200, 223, 227 multidisciplinary 100, 175
 - Techniques 79, 81, 136, 151, 176, 190, 202, 215 psychoanalytic 215 psycho-drama 202
 - Test 88, 93, 204, 205 affective distances 204, 205 neuropsychological 93 psychological 75, 88
 - Therapy 80, 167, 168, 174, 176, 178, 188, 198 cognitive behavioral 176 cognitive-behavioral 167, 168, 174, 178

- cognitive-behavioural 80, 188
 - psychoanalytic 198
 - Time-intensive treatments 171
 - Trained health psychologist 80
 - Trauma 25, 102, 104
 - peripheral skin 102
 - psychological 104
 - Treatment adherence 74, 82
 - improving 74
 - Treatment efficacy 141
 - Treatment failure 96
 - Treatment goals 157
 - patient-derived 135
 - Treatment modalities 108, 150
 - common 108
 - Treatment motivation 96
 - Treatment of skin picking disorder 105
 - Treatment of stress in psoriasis 41
 - Treatment prescriptions 172
 - Treatment regimen 81
 - Treatment repertoire 95
 - Treatment response 96, 147
 - Treatments of itch-scratching problems 177
 - Trichotillomania 13, 170, 178, 202, 226
 - Trusting patient-clinician relationship 155
 - Tumour necrosis factor (TNF) 8, 147
- U**
- Ulceration 102, 103, 111
 - Unimodal treatments 175
- V**
- Vasoactive intestinal peptide (VIP) 5, 7, 8, 10
 - Vicious cycle 26, 80, 81, 171, 172
 - Vulvar psoriasis 30
- W**
- WPAI outcomes 146